Japan Approves First Coronavirus Vaccine But Hurdles Ahead?
Pfizer Gets Nod But Challenges Ahead?
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
You may also be interested in...
Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization
A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.
Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.